ACADIA Pharmaceuticals Inc. Stock News

Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.

Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.